Skip to primary sidebar Search this website Home Company Products News & Releases Careers Contact Us OUR TECHNOLOGY MeltDose Drug Delivery Technology MeltDose drug delivery technology is used to enhance the oral bioavailability and control the release of a drug, especially low water-soluble or water-insoluble drugs. Particle size plays a vital role in bioavailability. Unlike conventional and nanocrystal drug delivery formulations which use larger particles that are more difficult to absorb, MeltDose technology enhances bioavailabilty by reducing the drug to the smallest possible particle size down to single molecules. The smaller particle size enables better dissolution and absorption. MeltDose technology achieves particle-size reduction by heating the active drug to create a “melt” solution. Particle Size MeltDose Technology: Single Molecule Nanocrystal Technology: 0.1-1µ Conventional Drug: 10µ The melt solution is then sprayed onto an inert particulate carrier (or “matrix”), using a patented nozzle. The matrix in MeltDose technology customizes release kinetics to achieve the desired timing and rate of release. MeltDose Process Sprayed Melted Drug Particles Customizable Matrix Tablet The drug and carrier solidifies into a state of solid solution, and the resulting granulate is compressed into a tablet. Patent Awarded MeltDose® technology is protected by a patent issued in May 2007 by the US Patent and Trademark Office, US Patent No. 7,217,431. The patent covers the method of making a particulate material containing a drug substance with low aqueous solubility using a unique controlled agglomeration process. IMPORTANT SAFETY INFORMATION What is the most important information I should know about ENVARSUS XR? ENVARSUS XR can cause serious side effects, including: Increased risk of cancer. People who take ENVARSUS XR have an increased risk of getting some kinds of cancer, including skin and lymph gland cancer (lymphoma). Increased risk of infection. ENVARSUS XR is a medicine that affects your immune system. ENVARSUS XR can lower the ability of your immune system to fight infections. Serious infections can happen in people receiving ENVARSUS XR that can cause death. Call your healthcare provider right away if you have symptoms of an infection such as: fever cough or flu-like symptoms warm, red, or painful areas on your skin sweats or chills muscle aches What is ENVARSUS XR? ENVARSUS XR is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. ENVARSUS XR is an extended-release tablet and is not the same as tacrolimus extended-release capsules, tacrolimus immediate-release capsules or tacrolimus for oral suspension. Your healthcare provider should decide what medicine is right for you. Who should not take ENVARSUS XR? Do not take ENVARSUS XR if you are allergic to tacrolimus or any of the ingredients in ENVARSUS XR. See the end of this leaflet for a complete list of ingredients in ENVARSUS XR. What should I tell my healthcare provider before taking ENVARSUS XR? Before you take ENVARSUS XR, tell your healthcare provider if you: plan to receive any live vaccines. Ask your healthcare provider if you are not sure if your vaccine is a live vaccine. have or have had liver, kidney or heart problems. have any other medical conditions. are pregnant or plan to become pregnant. ENVARSUS XR may harm your unborn baby. If you are able to become pregnant, you should use effective birth control before and during treatment with ENVARSUS XR. Talk to your healthcare provider about birth control methods that may be right for you. Males who have female partners that are able to become pregnant should also use effective birth control before and during treatment with ENVARSUS XR. Talk to your healthcare provider before starting treatment with ENVARSUS XR about birth control methods that may be right for you. are breastfeeding or plan to breastfeed. ENVARSUS XR passes into your breast milk. You and your healthcare provider should decide if you will breastfeed while taking ENVARSUS XR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, natural, herbal or nutritional supplements. ENVARSUS XR may affect the way other medicines work, and other medicines may affect how ENVARSUS XR works. How should I take ENVARSUS XR? Take ENVARSUS XR exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose of ENVARSUS XR if needed. Do not stop taking or change your dose of ENVARSUS XR without talking to your healthcare provider . Take ENVARSUS XR once daily with fluid (preferably water) on an empty stomach, at least 1 hour before or at least 2 hours after a meal, at the same time each day (preferably in the morning). Take ENVARSUS XR tablets whole. Do not chew, divide, crush, or dissolve ENVARSUS XR tablets before swallowing. If you cannot swallow ENVARSUS XR tablets whole, tell your healthcare provider. If you miss your dose of ENVARSUS XR, it should be taken as soon as possible, but no longer than 15 hours after missing your dose. If the time after you miss your dose is more than 15 hours, the missed dose should be skipped and the next dose should be taken the following morning at your regularly scheduled time. Do not take 2 doses at the same time. If you take too much ENVARSUS XR, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking ENVARSUS XR? Live vaccines such as flu vaccine through your nose, measles, mumps, rubella, polio by mouth, BCG (TB vaccine), yellow fever, chicken pox (varicella), or typhoid. Exposure to sunlight and UV light such as tanning machines. Wear protective clothing and use a sunscreen. You should not eat grapefruit or drink grapefruit juice while taking ENVARSUS XR. You should not drink alcohol while taking ENVARSUS XR. What are the possible side effects of ENVARSUS XR? ENVARSUS XR may cause serious side effects, including: See “What is the most important information I should know about ENVARSUS XR?” Problems from medication errors such as graft rejection and other serious reactions. People who take ENVARSUS XR have sometimes been given the wrong medicine because some medicines have the same ingredient (tacrolimus) as ENVARSUS XR. Check your ENVARSUS XR when you get a new prescription to make sure you have received the right medicine. Call your healthcare provider right away if you think you were given the wrong medicine. Ask your healthcare provider or pharmacist if you are not sure what ENVARSUS XR should look like. High blood sugar (diabetes). Your healthcare provider may do certain tests to check for diabetes while you take ENVARSUS XR. Call your healthcare provider right away if you have: frequent urination confusion fruity smell on your breath increased thirst or hunger drowsiness nausea, vomiting, or stomach pain blurred vision loss of appetite Kidney problems. Kidney problems are serious and common side effects of ENVARSUS XR. Your healthcare provider may do certain tests to check for kidney function while you take ENVARSUS XR. Nervous system problems. Nervous system problems are a serious and common side effect of ENVARSUS XR. Call your healthcare provider right away if you get any of these symptoms while taking ENVARSUS XR. These could be signs of a serious nervous system problems: confusion numbness and tingling vision changes coma headache muscle tremors seizures High levels of potassium in your blood. Your healthcare provider may do certain tests to check your potassium level while you take ENVARSUS XR. High blood pressure. Your healthcare provider will monitor your blood pressure while you take ENVARSUS XR. Changes in the electrical activity of your heart (QT prolongation). Severe low blood cell count (anemia) The most common side effects of ENVARSUS XR are, diarrhea, urinary tract infection, low red blood cell count (anemia), high blood pressure, and constipation. These are not all the possible side effects of ENVARSUS XR. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ENVARSUS XR? Store ENVARSUS XR at room temperature between 68° F to 77° F (20° C to 25° C). Safely throw away medicine that is out of date or no longer needed. Keep ENVARSUS XR and all medicines out of reach of children. General information about the safe and effective use of ENVARSUS XR. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ENVARSUS XR for a condition for which it was not prescribed. Do not give ENVARSUS XR to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about ENVARSUS XR. If you would like more information, talk with your healthcare provider . You can ask your pharmacist or healthcare provider for information about ENVARSUS XR that is written for health professionals. For more information, go to www.ENVARSUSXR.com or call 1-844-Veloxis (1-844-835-6947). What are the ingredients in ENVARSUS XR? Active ingredient: tacrolimus USP Inactive ingredients: hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF Manufactured by: Rottendorf Pharma GmbH, 59320 Ennigerloh, North Rhine-Westphalia, Germany Marketed by: Veloxis Pharmaceuticals, Inc. 1001 Winstead Dr, Suite 310, Cary, NC 27513, United States To report SUSPECTED ADVERSE REACTIONS, contact Veloxis Pharmaceuticals, Inc. at 1-844-VELOXIS (835-6947) or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. Primary Sidebar PRODUCTS Product Pipeline Development Our Technology ENVARSUS XR NEWS & RELEASES Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor Sep 8, 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market Apr 26, 2021 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program Jun 18, 2020 READ MORE ©2021 All rights reserved. Veloxis Pharmaceuticals, Inc. US-UNB-2100005 7/21 Info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT